DJIA 17,191.37 -195.84 -1.13%
NASDAQ 4,637.99 -43.50 -0.93%
S&P 500 2,002.16 -27.39 -1.35%
market minute promo

Gilead Sciences (NASDAQ: GILD)

102.45 -2.58 (-2.46%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GILD $102.45 -2.46%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $105.32
Previous Close $105.03
Daily Range $102.35 - $105.50
52-Week Range $63.50 - $116.83
Market Cap $154.6B
P/E Ratio 18.62
Dividend (Yield) $0.00 (0.0%)
Volume 11,393,808
Average Daily Volume 19,434,027
Current FY EPS $7.80





Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website:

News & Commentary Rss Feed

Pfizer, Inc. Should Forget AstraZeneca and Buy This Company Instead

3 Motley Fool contributors offer up suggestions on what they believe Pfizer should acquire.

Is AbbVie (ABBV) Set to Beat 4Q Earnings on Humira Sales? - Analyst Blog

Can Gilead Beat AbbVie At Its Own Game?

Can Regulus Therapeutics Double Again on Next Hep-C Drug Trial Update?

Cancer biotech Kolltan Pharmaceuticals withdraws $86 million IPO

Short Sellers Starting to Gang Up on Biotech

Gilead Includes Pan-Genotypic Agent in HCV Licensing Deals - Analyst Blog

3 Stocks Dragging The Health Care Sector Downward

Celgene: Could You Be More Like Gilead, Please?

This Telling Figure Insinuates Big Pharma Could Be in Big Trouble

Could this truly terrifying data difference spell doom for Big Pharma in 2015?

See More GILD News...

GILD's Top Competitors

GILD $102.45 (-2.46%)
Current stock: GILD
AMGN $154.64 (-2.67%)
Current stock: AMGN
CELG $118.97 (-2.77%)
Current stock: CELG
$0.00 (0.00%)
Current stock: